Health TrialsbyHealthPanel

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

ConditionsOncologyBreast CancerProstate CancerGynecologic CancerBrain TumorBrain CancerGynecologic TumorProstate TumorProstate NeoplasmBreast TumorRadiation ToxicityQuality of LifeRectal CancerRectal TumorRectal NeoplasmsLung CancerLung TumorLung NeoplasmEsophageal CancerEsophagus CancerEsophageal TumorEsophageal NeoplasmEsophagus TumorEsophagus NeoplasmPancreatic CancerPancreatic TumorPancreatic NeoplasmsHead and Neck CancerHead and Neck NeoplasmsHead and Neck TumorTumorNeoplasmsBladder CancerBladder NeoplasmLiver CancerLiver NeoplasmsLiver MetastasesOligometastases
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUMC Utrecht

About this trial

The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patient is to undergo or has completed imaging or treatment procedures on an MR-Linac;

Patient provides written, informed consent;

Patient is 18 years old or older.

Disqualifiers

MRI exclusion criteria, including

MRI contraindications as per usual clinical care, such as (possible) pregnancy; claustrophobia and metal or electronic implants not compatible with MRI.

Trial population

Patients receiving treatment and/or imaging on an MR-Linac machine are eligible for enrolment. Patients must meet eligibility criteria and provide informed consent to be enrolled.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Radiation therapy

    Radiation

    Radiation therapy on the CE marked and FDA approved MR-Linac

Treatment groups

8,000 Participants
are divided into 13 treatment groups

13

Treatment groups

See each treatment group below.

Group A: Brain cancer1 intervention
Group B: Lung cancer1 intervention
Group C: Esophageal cancer1 intervention
Group D: Breast Cancer1 intervention
Group E: Head and Neck Cancer1 intervention
Group F: Pancreatic cancer1 intervention
Group G: Gynecological cancer1 intervention
Group H: Rectal cancer1 intervention
Group I: Prostate cancer1 intervention
Group J: Bladder cancer1 intervention
Group K: Oligometastases1 intervention
Group L: Liver cancer1 intervention
Group M: Other types of cancer1 intervention

Trial outcomes

Primary outcomes

1

Progression-free Survival

Progression free survival of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.

Time frame
3 months after MR-Linac treatment
2

Progression-free Survival

Progression free survival of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.

Time frame
6 months after MR-Linac treatment
3

Progression-free Survival

Progression free survival of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.

Time frame
24 months after MR-Linac treatment
4

Survival

Overall survival of participating patients will be obtained from the hospital information systems. Patient follow-up is conducted to local standard of care practices.

Time frame
3 months after MR-Linac treatment

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

UMC Utrecht

Lead sponsor

The Netherlands Cancer Institute

Collaborator

Sunnybrook Health Sciences Centre

Collaborator

M.D. Anderson Cancer Center

Collaborator

The Christie NHS Foundation Trust

Collaborator

Royal Marsden NHS Foundation Trust

Collaborator

Medical College of Wisconsin

Collaborator

Elekta Limited

Collaborator

Odense University Hospital

Collaborator

Radboud University Medical Center

Collaborator

Radiotherapiegroep

Collaborator

Jules Bordet Institute

Collaborator

University Hospital Tuebingen

Collaborator

Radiotherapeutic Institute Friesland

Collaborator

Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

Collaborator

IRCCS Sacro Cuore Don Calabria di Negrar

Collaborator

Austin Health

Collaborator

Princess Margaret Hospital, Canada

Collaborator

Università degli Studi di Brescia

Collaborator

Source ClinicalTrials.gov
Apply now